OBJECTIVES: Several studies show that in developing countries, low–income patients use low price counterfeit drugs provided by the illegal drug market. In Cameroon, those false drugs represent 40% of the street market and lead to malaria therapeutic failure and inappropriate medical expenses. The Yaoundé program aims to improve access to efficient antimalarial drugs by providing a differentiated price policy through the official private pharmacy distribution sector,allowing access to efficient antimalarials to low–income population which would otherwise use street market drugs. METHODS: In 31 retail pharmacies of Yaoundé, artesunate (Arsumax®)was made available at a “no profit no loss” public price of 1170FCFA (1.78€) instead of 3400FCFA (5.8€),ie:- 66%.Eligibility of patients was based on income below the poverty level (established by the Ministry of Economy as 30€ monthly households incomes per number of dependences).Program effectiveness was assessed by evaluating the number of new patients having access to this lower price Arsumax®. RESULTS: After 6 months of implementation, patients having access to the lower price Arsumax® increased up to 38% of population buying Arsumax® at normal price (3673 / 9641). During the same period, we notice no consumption decrease for others antimalarials of the same therapeutic group. Patients and pharmacists have strictly observed the program procedures. CONCLUSION: This study shows that a differentiated price policy allows efficient access to high quality antimalarial drugs for low-income population, through the private drug distribution system. Moreover this program is running without any financing support from the government or international funding. Based on this test, the program is being implemented over the entire country and to other African countries.